Adjusted financial outlook for 2022

Orphazyme A/S
Company announcement 
No. 35/2022        

                
www.orphazyme.com
Company Registration No. 32266355

Copenhagen, Denmark, September 25, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) has determined to regulate its outlook for 2022, as revealed on June 7, 2022. The change is pushed by the separation of actions into persevering with and discontinued operations. The discontinued actions are associated to the sale of belongings to KemPharm A/S. The persevering with business actions are the restricted ongoing operational business actions with solely two staff. For the full-year 2022, we anticipate a loss from persevering with operations within the vary DKK 40 – 45 million and a optimistic outcome from discontinued operations referring to the Sale of Assets to KemPharm of DKK 87.4 million (beforehand working revenue within the vary DKK 10 – 30 million). As beforehand communicated, we count on to finish 2022 with greater than DKK 30 million in money and equivalents.

For further info, please contact

Orphazyme A/S

Anders Vadsholt, Chief Executive Officer and Chief Financial Officer +45 28 98 90 55

Forward-looking assertion
This firm announcement might comprise sure forward-looking statements inside the which means of the Private Securities Litigation Reform Act of 1995, together with in respect of the corporate’s anticipated working plans and efficiency, financial place and skill to function as a going concern. Although the Company believes its expectations are based mostly on affordable assumptions, all statements apart from statements of historic truth included on this firm announcement about future occasions are topic to (i) change with out discover and (ii) elements past the Company’s management, together with actions by regulatory businesses, results of the worldwide COVID-19 pandemic, and the affect of the Company’s Sale of Assets. These statements might embody, with out limitation, any statements preceded by, adopted by, or together with phrases akin to “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and different phrases and phrases of comparable which means or the detrimental thereof. Forward-looking statements are topic to inherent dangers and uncertainties past the Company’s management that might trigger the Company’s precise outcomes, efficiency, or achievements to be materially totally different from the anticipated outcomes, efficiency, or achievements expressed or implied by such forward-looking statements. In mild of those dangers and uncertainties, and different dangers and uncertainties which can be described within the Risk Factors part and different sections of the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 2, 2021, and different filings that the Company makes with the SEC infrequently (which can be found at http://www.sec.gov), the occasions and circumstances mentioned in such forward-looking statements might not happen, and the Company’s precise outcomes may differ materially and adversely from these anticipated or implied thereby. Although the Company’s forward-looking statements mirror the nice religion judgment of its administration, these statements are based mostly solely on info and elements at present recognized by the Company. As a outcome, you might be cautioned to not depend on these forward-looking statements. Except as required by regulation, the Company assumes no obligation to replace these forward-looking statements publicly, or to replace the explanations precise outcomes may differ materially from these anticipated within the forward-looking statements, even when new info turns into accessible sooner or later.

• 35-2022 Adjusted financial outlook for 2022